Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“TIP: Ph II trial in mESCC w/ severe dysphagia Stage IVB, untreated.
- FP+ICI vs RT/CRT → FP+ICI
- Primary EP: dysphagia relief at 9w
- Will clarify if upfront RT/CRT improves sx control in ICI era for high-risk pts. “
Title: A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia
Authors: Y. Nagata, H. Arai, N. Izawa, C. Inagaki, A. Sugaya, K. Hirata, T. Tsushima, T. Moriwaki, T. Masuishi, Y. Nagatani, K. Harada, M. Taguri, Y. Sunakawa.
Other articles featuring Nieves Martinez Lago on OncoDaily.
